NeoGenomics (NASDAQ: NEO), a leading provider of cancer diagnostic solutions, announced today that it will present eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will highlight the company's latest advancements in minimal residual disease (MRD) detection, precision oncology, and real-world evidence. The ASCO meeting is scheduled to take place from May 29 to June 2 in Chicago.
According to the company's announcement, the research to be presented spans several cutting-edge areas, including hematologic malignancies, genomic profiling of solid tumors, the real-world impact of insurance coverage gaps on next-generation sequencing testing, and circulating tumor DNA detection via MRD assays.
Notably, NeoGenomics will present an interim analysis of a colorectal cancer cohort study conducted in collaboration with MD Anderson Cancer Center, showcasing the application of its RaDaR® ST assay technology. Furthermore, to support its biopharmaceutical partners in advancing targeted therapies such as antibody-drug conjugates and bispecific antibodies, the company will highlight several novel biomarkers, including B7-H3 and CD137. NeoGenomics is also developing a low-input sample MRD detection method for acute myeloid leukemia, which is expected to provide higher sensitivity and faster turnaround times with limited sample volumes.
Tony Zook, Chief Executive Officer of NeoGenomics, stated, "Cancer diagnosis is the starting point of a long journey, and NeoGenomics is committed to supporting patients from initial diagnosis through recurrence monitoring. The breadth of research we are presenting at ASCO reflects our commitment to providing personalized answers for every cancer patient."
Financially, NeoGenomics continues to demonstrate steady growth. The company's first-quarter 2026 results reported total revenue of $187 million, an 11% year-over-year increase, marking a record high for a first quarter. Clinical test revenue grew by 14%, and next-generation sequencing business revenue increased by 26%. The net loss narrowed by 34% year-over-year to $17 million. Adjusted EBITDA reached $9 million, a 27% increase compared to the prior year. The company has raised its full-year 2026 revenue guidance to a range of $797 million to $803 million.
The RaDaR® ST MRD assay for various solid tumor types, launched by the company in February of this year, is estimated to address a market opportunity exceeding $20 billion, with current penetration in this segment still below 10%. Investors will be closely monitoring the feedback on the research presented at the ASCO meeting and its potential to drive further growth in the NGS business and improve gross margins.
Comments